老虎证券

BUZZ-H.C. Wainwright starts coverage of Galectin Therapeutics with 'buy'

Reuters
06-17
BUZZ-H.C. Wainwright starts coverage of Galectin <a href="https://laohu8.com/S/LENZ">Therapeutics</a> with 'buy'

** H.C. Wainwright initiates coverage of drug developer Galectin Therapeutics GALT.O with 'buy' rating; sets PT at $6, which is ~233.3% upside on stock's last close

** Brokerage says Galectin is currently developing belapectin to treat chronic liver disease called metabolic dysfunction-associated steatohepatitis (MASH), which can progress to cirrhosis, liver failure and liver cancer

** H.C. Wainwright says GALT's belapectin is only therapy in development for MASH cirrhosis

** "Initial clinical trials exhibited compelling trends towards preventing and halting signs and symptoms of the disease," brokerage says

** Including session's moves, stock up ~45% YTD

(Reporting by Prakhar Srivastava in Bengaluru)

((Prakhar.srivastava2@thomsonreuters.com))

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10